Eikenboom, Ellis L.
Nasar, Naaz
Seier, Kenneth
Gönen, Mithat
Spaander, Manon C. W.
O’Reilly, Eileen M.
Jarnagin, William R.
Drebin, Jeffrey
D’Angelica, Michael I.
Kingham, T. Peter
Balachandran, Vinod P.
Soares, Kevin C.
Wagner, Anja
Wei, Alice C. https://orcid.org/0000-0002-2505-959X
Funding for this research was provided by:
NIH/NCI Cancer Center Support Grant (P30 CA008748)
Article History
Received: 7 June 2024
Accepted: 19 November 2024
First Online: 10 December 2024
Disclosure
: Eileen M. O’Reilly reports research funding to Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, and Digestive Care, Break Through Cancer, as well as consulting/DSMB for Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus Agios (spouse), Genentech-Roche (spouse), Eisai (spouse), Servier (spouse). Jeffrey Drebin reports employment and leadership at American Regent (spouse) and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals and Ions pharmaceuticals. Vinod P. Balachandran reports research funding from Genetech/Roche and was an inventor on patent applications related to antigen cross-reactivity and neoantigen quality modeling. Alice C. Wei reports consulting for Histosonics and clinical trial funding from Ipsen. The remaining authors have no conflicts of interest.